Experience-Based Quality Control in Radiation Therapy Treatment Planning of High Risk Post-prostatectomy Prostate Cancer with RapidPlan: NRG Oncology RTOG 0621

被引：0
|
作者：
O'Grady, F. [1 ]
Geng, H. [1 ]
Zhong, H. [2 ]
Huang, M. [1 ]
Giaddui, T. G. [1 ]
Hurwitz, M. D. [3 ]
Xiao, Y. [2 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[3] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 99卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2017.06.1219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2616
引用
收藏
页码：E257 / E258
页数：2
相关论文
共 50 条
  • [41] IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES
    Fossati, Nicola
    Karnes, R. Jeffrey
    Cozzarini, Cesare
    Fiorino, Claudio
    Joniau, Steven
    Hinkelbein, Wolfgang
    Haustermans, Karin
    Tombal, Bertrand
    Shariat, Shahrokh F.
    Karakiewicz, Pierre I.
    Goldner, Gregor
    Montorsi, Francesco
    Van Poppel, Hein
    Wiegel, Thomas
    Briganti, Alberto
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1089 - E1089
  • [42] Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer
    Nguyen, P. L.
    Huang, H. C.
    Davicioni, E.
    Sandler, H. M.
    Shipley, W. U.
    Efstathiou, J. A.
    Simko, J.
    Pollack, A.
    Dicker, A. P.
    Roach, M.
    Rosenthal, S. A.
    Morginstin, M.
    Mendez, L.
    Hartford, A. C.
    Hall, W. A.
    Desai, A. B.
    Rabinovitch, R.
    Peters, C. A.
    Rodgers, J.
    Feng, F. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S50 - S50
  • [43] Stereotactic Body Radiation Therapy for Low-, Intermediate-, and High-Risk Prostate Cancer: Disease Control and Quality of Life at 6 Years
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S24 - S25
  • [44] Stereotactic body radiation therapy for low-, intermediate- and high-risk prostate cancer: Disease control and quality of life at 9 years
    Katz, Alan J.
    Kang, Josephine
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [45] Dosimetric Advantages And Superior Treatment Delivery Efficiency Of RapidArc Over Conventional Intensity Modulated Radiation Therapy In Radiation Therapy Planning For High Risk Prostate Cancer Involving Seminal Vesicles And Pelvic Nodes
    Poon, D.
    Leung, C.
    Kam, M.
    Leung, S.
    Wong, S.
    Kung, S.
    Lee, W.
    Yu, B.
    Chan, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S442 - S442
  • [46] Preliminary updated results of a phase I/II trial using trimodality therapy in patients with post-prostatectomy high risk pathologic (p) T2-3N0M0 prostate cancer
    Kumar, Parvesh
    Van Veldhuizen, Peter J.
    Thompson, Mark
    Shen, Xinglei
    Coster, James
    Pinskl, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Applicability of a Point Fiducial-Based Model for the Prostatic Bed in Post-Prostatectomy Radiation Therapy Patients: An Expedited Dosimetric Analysis Using New Functionality in Philips' Pinnacle3 Treatment Planning System's Research Version
    Bharat, S.
    Zhu, M.
    Gay, H.
    Michalski, J.
    Santanam, L.
    Noel, C.
    Parikh, P.
    MEDICAL PHYSICS, 2011, 38 (06)
  • [48] Results of a phase I-II trial using tri-modality therapy in patients with post-prostatectomy high risk pathologic (p) T2-3N0M0 prostate cancer.
    Kumar, Parvesh
    Van Veldhuizen, Peter
    Thompson, Mark
    Shen, Xinglei
    Pinski, Jacek K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] RTOG/NRG 1115 Quality of Life of Phase III Dose Escalated Radiation Therapy (RT) and Standard Androgen Deprivation Therapy (ADT) with GnRH Agonist vs. Dose Escalated RT and ADT with GnRH Agonist and Orteronel (TAK-700) for Men with High-Risk Prostate
    Bruner, D. W.
    Pugh, S.
    Michaelson, D.
    Hamstra, D. A.
    Bachand, F.
    Master, V.
    Torres, M.
    Kaplan, I. D.
    Rosenthal, S. A.
    Roach, M., III
    Raben, A.
    Michalski, J. M.
    Kavadi, V. S.
    Ferguson, M.
    Morgan, S. C.
    D'Souza, D. P.
    DeMora, L.
    Sandler, H. M.
    Movsas, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E214 - E214
  • [50] Re: A Genomic Classifier Improves Prediction of Metastatic Disease within 5 Years after Surgery in Node-Negative High-Risk Prostate Cancer Patients Managed by Radical Prostatectomy without Adjuvant Therapy - Re: Tissue-Based Genomics Augments Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 195 (01): : 95 - 95
12345